{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:44:16Z","timestamp":1792619056002,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T00:00:00Z","timestamp":1605312000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T00:00:00Z","timestamp":1605312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis was performed to compare the clinicopathological features and survival outcomes between sarcomatoid variant (SV)-urothelial carcinoma of the bladder (UCB) and conventional UCB (C-UCB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive search of PubMed, Embase, and Cochrane Library was performed. Endpoints included clinicopathological features and survival outcomes (overall survival [OS], cancer-specific survival [CSS], and progression-free survival [PFS]). The survival benefits of neoadjuvant chemotherapy (NAC) or adjuvant chemotherapy (AC) for SV-UCB also have been studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 8 observational studies were included. Patients with SV-UCB had a higher rate of\u2009\u2265\u2009stage pT3 (odds ratio [OR], 2.06; 95% confidence interval [CI], 1.64\u20132.59; p\u2009&lt;\u20090.001) and a lower rate of concomitant carcinoma in situ (OR, 0.25; 95% CI, 0.09\u20130.72; p\u2009=\u20090.010). The other clinicopathological variables were similar between SV-UCB and C-UCB. With unadjusted data, patients with SV-UCB had a significant inferior OS (HR, 1.24; 95% CI, 1.07\u20131.44; p\u2009=\u20090.004) and CSS (HR, 2.08; 95% CI, 1.63\u20132.66; p\u2009&lt;\u20090.001). However, after adjusted, SV-UCB had worse OS (HR, 1.41; 95% CI, 0.95\u20132.08; p\u2009=\u20090.090) and CSS (HR, 1.54; 95% CI, 0.95\u20132.52; p\u2009=\u20090.080) approaching the borderline of significance. For SV-UCB, NAC (HR, 0.73; 95% CI, 0.51\u20131.05; p\u2009=\u20090.090) and AC (HR, 0.88; 95% CI, 0.66\u20131.17; p\u2009=\u20090.370) seemed to have no benefit on OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared to C-UCB, SV-UCB was associated with more advanced disease and more inferior OS and CSS. NAC and AC had no survival benefit for SV-UCB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12935-020-01626-9","type":"journal-article","created":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T01:02:28Z","timestamp":1605315748000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Sarcomatoid variant urothelial carcinoma of the bladder: a systematic review and meta-analysis of the clinicopathological features and survival outcomes"],"prefix":"10.1186","volume":"20","author":[{"given":"Liangyou","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baojun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingbo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xupeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6908-6768","authenticated-orcid":false,"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,14]]},"reference":[{"issue":"4","key":"1626_CR1","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.euf.2019.09.003","volume":"6","author":"N Lobo","year":"2019","unstructured":"Lobo N, Shariat SF, Guo CC, Fernandez MI, Kassouf W, Choudhury A, et al. What is the significance of variant histology in urothelial carcinoma? Eur Urol Focus. 2019;6(4):653\u201363.","journal-title":"Eur Urol Focus."},{"issue":"1","key":"1626_CR2","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","volume":"70","author":"PA Humphrey","year":"2016","unstructured":"Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-part b: prostate and bladder tumours. Eur Urol. 2016;70(1):106\u201319.","journal-title":"Eur Urol"},{"issue":"6","key":"1626_CR3","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1016\/j.juro.2007.08.038","volume":"178","author":"JL Wright","year":"2007","unstructured":"Wright JL, Black PC, Brown GA, Porter MP, Kamat AM, Dinney CP, et al. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol. 2007;178(6):2302\u20136 ((discussion 7)).","journal-title":"J Urol"},{"issue":"3","key":"1626_CR4","first-page":"7783","volume":"22","author":"N Fatima","year":"2015","unstructured":"Fatima N, Canter DJ, Carthon BC, Kucuk O, Master VA, Nieh PT, et al. Sarcomatoid urothelial carcinoma of the bladder: a contemporary clinicopathologic analysis of 37 cases. Can J Urol. 2015;22(3):7783\u20137.","journal-title":"Can J Urol"},{"issue":"5","key":"1626_CR5","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.clgc.2016.03.004","volume":"14","author":"M Malla","year":"2016","unstructured":"Malla M, Wang JF, Trepeta R, Feng A, Wang J. Sarcomatoid Carcinoma of the Urinary Bladder. Clin Genitourin Cancer. 2016;14(5):366\u201372.","journal-title":"Clin Genitourin Cancer"},{"issue":"9","key":"1626_CR6","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/cncr.31952","volume":"125","author":"S Berg","year":"2019","unstructured":"Berg S, D\u2019Andrea D, Vetterlein MW, Cole AP, Fletcher SA, Krimphove MJ, et al. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter? Cancer. 2019;125(9):1449\u201358.","journal-title":"Cancer"},{"issue":"22","key":"1626_CR7","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1002\/cncr.30907","volume":"123","author":"MW Vetterlein","year":"2017","unstructured":"Vetterlein MW, Wankowicz SAM, Seisen T, Lander R, Loppenberg B, Chun FK, et al. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Cancer. 2017;123(22):4346\u201355.","journal-title":"Cancer"},{"key":"1626_CR8","doi-asserted-by":"publisher","first-page":"454792","DOI":"10.1155\/2010\/454792","volume":"2010","author":"J Wang","year":"2010","unstructured":"Wang J, Wang FW, Lagrange CA, Hemstreet Iii GP, Kessinger A. Clinical features of sarcomatoid carcinoma (carcinosarcoma) of the urinary bladder: analysis of 221 cases. Sarcoma. 2010;2010:454792.","journal-title":"Sarcoma."},{"issue":"7","key":"1626_CR9","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s00345-016-1962-8","volume":"35","author":"W Sui","year":"2017","unstructured":"Sui W, Matulay JT, Onyeji IC, Theofanides MC, James MB, RoyChoudhury A, et al. Contemporary treatment patterns and outcomes of sarcomatoid bladder cancer. World J Urol. 2017;35(7):1055\u201361.","journal-title":"World J Urol"},{"issue":"1","key":"1626_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1590\/s1677-5538.ibju.2016.0347","volume":"44","author":"SP Robinson","year":"2018","unstructured":"Robinson SP, Farooq A, Laniado M, Motiwala H. The demographic features, clinical outcomes, prognosis and treatment options for patients with sarcomatoid carcinoma of the urinary bladder: a single centre experience. Int Braz J Urol. 2018;44(1):45\u201352.","journal-title":"Int Braz J Urol"},{"issue":"6","key":"1626_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.urolonc.2016.12.006","volume":"35","author":"M Moschini","year":"2017","unstructured":"Moschini M, Dell\u2019Oglio P, Luciano R, Gandaglia G, Soria F, Mattei A, et al. Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. Urol Oncol. 2017;35(6):335\u201341.","journal-title":"Urol Oncol"},{"issue":"1","key":"1626_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.urolonc.2014.10.001","volume":"33","author":"MF Monn","year":"2015","unstructured":"Monn MF, Kaimakliotis HZ, Pedrosa JA, Cary KC, Bihrle R, Cheng L, et al. Contemporary bladder cancer: variant histology may be a significant driver of disease. Urol Oncol. 2015;33(1):18.","journal-title":"Urol Oncol"},{"key":"1626_CR13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.urology.2016.01.048","volume":"93","author":"AM Luchey","year":"2016","unstructured":"Luchey AM, Manimala NJ, Dickinson S, Dhillon J, Agarwal G, Lockhart JL, et al. Change in management based on pathologic second opinion among bladder cancer patients presenting to a comprehensive cancer center: implications for clinical practice. Urology. 2016;93:130\u20134.","journal-title":"Urology"},{"issue":"8","key":"1626_CR14","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.urolonc.2012.04.009","volume":"31","author":"RB Shah","year":"2013","unstructured":"Shah RB, Montgomery JS, Montie JE, Kunju LP. Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital. Urol Oncol. 2013;31(8):1650\u20135.","journal-title":"Urol Oncol"},{"key":"1626_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.","journal-title":"Trials"},{"key":"1626_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2288-14-45","volume":"14","author":"CK Lo","year":"2014","unstructured":"Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers\u2019 to authors\u2019 assessments. BMC Med Res Methodol. 2014;14:45.","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"1626_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401\u20136.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"1626_CR18","first-page":"175","volume":"2","author":"J Wang","year":"2011","unstructured":"Wang J, Gillaspie C, Kunadharaju R, Talmon GA, Enke C. Sarcomatoid urothelial carcinoma: a single cancer center experience. World J Oncol. 2011;2(4):175\u201380.","journal-title":"World J Oncol"},{"issue":"6","key":"1626_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.euo.2019.09.003","volume":"2","author":"E Veskimae","year":"2019","unstructured":"Veskimae E, Espinos EL, Bruins HM, Yuan Y, Sylvester R, Kamat AM, et al. what is the prognostic and clinical importance of urothelial and nonurothelial histological variants of bladder cancer in predicting oncological outcomes in patients with muscle-invasive and metastatic bladder cancer? A European Association of urology muscle invasive and metastatic bladder cancer guidelines panel systematic review. Eur Urol Oncol. 2019;2(6):625\u201342.","journal-title":"Eur Urol Oncol"},{"issue":"19","key":"1626_CR20","first-page":"335","volume":"106","author":"JB du Prel","year":"2009","unstructured":"du Prel JB, Hommel G, Rohrig B, Blettner M. Confidence interval or p-value?: part 4 of a series on evaluation of scientific publications. Dtsch Arztebl Int. 2009;106(19):335\u20139.","journal-title":"Dtsch Arztebl Int"},{"key":"1626_CR21","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/S0022-5347(18)31722-1","volume":"177","author":"PCKW Black","year":"2007","unstructured":"Black PCKW, Brown GA. Variant histology in bladder cancer-Experience in 1246 patients undergoing cystec-tomy. J Urol. 2007;177:502.","journal-title":"J Urol"},{"issue":"5","key":"1626_CR22","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.humpath.2006.11.014","volume":"38","author":"PE Spiess","year":"2007","unstructured":"Spiess PE, Tuziak T, Tibbs RF, Bassett R, Tamboli P, Brown GA, et al. Pseudosarcomatous and sarcomatous proliferations of the bladder. Hum Pathol. 2007;38(5):753\u201361.","journal-title":"Hum Pathol"},{"issue":"3","key":"1626_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3747\/co.v16i3.396","volume":"16","author":"JB Wallach","year":"2009","unstructured":"Wallach JB, Wang B, Sanfilippo N. High-grade hyperinvasive sarcomatoid urothelial bladder carcinoma demonstrating complete response to bladder-preserving chemoradiation. Curr Oncol. 2009;16(3):55\u20137.","journal-title":"Curr Oncol"},{"issue":"1","key":"1626_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1442-2042.2006.01600.x","volume":"14","author":"S Hoshi","year":"2007","unstructured":"Hoshi S, Sasaki M, Muto A, Suzuki K, Kobayashi T, Tukigi M, et al. Case of carcinosarcoma of urinary bladder obtained a pathologically complete response by neoadjuvant chemoradiotherapy. Int J Urol. 2007;14(1):79\u201381.","journal-title":"Int J Urol"},{"issue":"7","key":"1626_CR25","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1136\/jclinpath-2012-201271","volume":"66","author":"CO Sung","year":"2013","unstructured":"Sung CO, Choi H, Lee KW, Kim SH. Sarcomatoid carcinoma represents a complete phenotype with various pathways of epithelial mesenchymal transition. J Clin Pathol. 2013;66(7):601\u20136.","journal-title":"J Clin Pathol"},{"issue":"5","key":"1626_CR26","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1097\/PAS.0b013e3182159dec","volume":"35","author":"L Cheng","year":"2011","unstructured":"Cheng L, Zhang S, Alexander R, Maclennan GT, Hodges KB, Harrison BT, et al. Sarcomatoid carcinoma of the urinary bladder: the final common pathway of urothelial carcinoma dedifferentiation. Am J Surg Pathol. 2011;35(5):e34-46.","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"1626_CR27","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1158\/2326-6066.CIR-15-0150","volume":"3","author":"RW Joseph","year":"2015","unstructured":"Joseph RW, Millis SZ, Carballido EM, Bryant D, Gatalica Z, Reddy S, et al. PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation. Cancer Immunol Res. 2015;3(12):1303\u20137.","journal-title":"Cancer Immunol Res"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-020-01626-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12935-020-01626-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-020-01626-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T12:04:00Z","timestamp":1605355440000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-020-01626-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,14]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1626"],"URL":"https:\/\/doi.org\/10.1186\/s12935-020-01626-9","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,14]]},"assertion":[{"value":"4 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"550"}}